Enveric Biosciences receives Nasdaq delisting notice on Nov 20 for bid price failure

Enveric Biosciences, Inc.

Nasdaq notified Enveric on Nov 20, 2024, that it failed to meet the $1.00 minimum bid price requirement by the Nov 12 compliance deadline.
Company not eligible for a second 180-day extension due to insufficient stockholders' equity (below $5M initial listing requirement).
Enveric intends to appeal and request a hearing before the Nasdaq Listing Qualifications Panel.
Appeal stays delisting and trading suspension pending Panel decision; no guarantee of favorable outcome.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.